Recent years have witnessed remarkable progresses in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as https://darrenzacv410101.prublogger.com/37908347/novel-therapeutic-targets-in-diabetes-retatrutide-and-trizepatide